{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:08:28Z","timestamp":1791875308808,"version":"4.3.4"},"reference-count":139,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Central serous chorioretinopathy (CSC) is a pachychoroid spectrum disease characterized by serous detachment of the neurosensory retina with subretinal fluid in young and middle-aged adults. The pathogenesis of CSC is not yet fully understood. However, it is considered a multifactorial disease that is strongly associated with choroidal dysfunction or vascular engorgement. Although there is no consensus on the treatment of CSC, photodynamic therapy has been effectively used to manage serous retinal detachment (SRD) in CSC. Moreover, micropulse diode laser photocoagulation and focal laser treatment have also been used. Recently, oral medications, including mineralocorticoid receptor antagonists, have been proposed for the management of CSC. Multimodal imaging plays a significant role in the diagnosis and treatment of CSC. Optical coherence tomography angiography (OCTA) has the advantage of detecting vascular flow in the retina and choroid layer, allowing for a better understanding of the pathology, severity, prognosis, and chronicity of CSC. In addition, early detection of choroidal neovascularization in CSC is possible using OCTA. This review article aims to provide a comprehensive and updated understanding of CSC, focusing on treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2211-5056.362040","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:42:33Z","timestamp":1669596153000},"page":"394-408","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Central serous chorioretinopathy"],"prefix":"10.4103","volume":"12","author":[{"given":"Jong Beom","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240830","first-page":"l1","article-title":"Pathogenesis of disciform detachment of the neuroepithelium","volume":"63","author":"Gass","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"R2-3-20240830","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: Update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R3-3-20240830","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R4-3-20240830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000310315","article-title":"Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit","volume":"205","author":"Yamada","year":"1992","journal-title":"Ophthalmologica"},{"key":"R5-3-20240830","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00006982-199414030-00008","article-title":"Central serous chorioretinopathy and indocyanine green angiography","volume":"14","author":"Piccolino","year":"1994","journal-title":"Retina"},{"key":"R6-3-20240830","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006982-199616030-00004","article-title":"Indocyanine green videoangiography of older patients with central serous chorioretinopathy","volume":"16","author":"Spaide","year":"1996","journal-title":"Retina"},{"key":"R7-3-20240830","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"R8-3-20240830","doi-asserted-by":"crossref","first-page":"e66858","DOI":"10.1371\/journal.pone.0066858","article-title":"Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: A population-based study","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"key":"R9-3-20240830","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","article-title":"Risk factors for central serous chorioretinopathy: A case-control study","volume":"111","author":"Haimovici","year":"2004","journal-title":"Ophthalmology"},{"key":"R10-3-20240830","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/ph13110359","article-title":"Central serous chorioretinopathy: Treatment with laser","volume":"13","author":"Battaglia Parodi","year":"2020","journal-title":"Pharmaceuticals (Basel"},{"key":"R11-3-20240830","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","article-title":"Central serous chorioretinopathy: A review of epidemiology and pathophysiology","volume":"41","author":"Liew","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"R12-3-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2017.06.008","article-title":"Central serous chorioretinopathy and glucocorticoids: An update on evidence for association","volume":"63","author":"Nicholson","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"R13-3-20240830","first-page":"1131","article-title":"In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy","volume":"11","author":"Bazzazi","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R14-3-20240830","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02713683.2013.824986","article-title":"Obstructive sleep apnea in patients with central serous chorioretinopathy","volume":"39","author":"Yava\u015f","year":"2014","journal-title":"Curr Eye Res"},{"key":"R15-3-20240830","first-page":"456","article-title":"Activation of the hypothalamic-pituitary-adrenal stress axis induces cellular oxidative stress","volume":"8","author":"Spiers","year":"2014","journal-title":"Front Neurosci"},{"key":"R16-3-20240830","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4330\/wjc.v7.i3.134","article-title":"Role of Helicobacter pylori infection in pathogenesis of atherosclerosis","volume":"7","author":"Vijayvergiya","year":"2015","journal-title":"World J Cardiol"},{"key":"R17-3-20240830","first-page":"475","article-title":"Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors","volume":"72","author":"Smal","year":"2017","journal-title":"Rev Med Liege"},{"key":"R18-3-20240830","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4103\/0974-9233.97920","article-title":"Incidence and natural course of symptomatic central serous chorioretinopathy in pregnant women in a maternity hospital in Kuwait","volume":"19","author":"Said-Ahmed","year":"2012","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R19-3-20240830","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40942-018-0108-0","article-title":"Comparative analysis of choroidal thickness in third trimester pregnant women","volume":"4","author":"Benfica","year":"2018","journal-title":"Int J Retina Vitreous"},{"key":"R20-3-20240830","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3341\/kjo.2012.26.4.260","article-title":"Systemic factors associated with central serous chorioretinopathy in Koreans","volume":"26","author":"Eom","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"R21-3-20240830","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/02713683.2016.1276196","article-title":"Risk factors for central serous chorioretinopathy: Multivariate approach in a case-control study","volume":"42","author":"Chatziralli","year":"2017","journal-title":"Curr Eye Res"},{"key":"R22-3-20240830","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.68.11.815","article-title":"Long-term follow-up of central serous chorioretinopathy","volume":"68","author":"Gilbert","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R23-3-20240830","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","article-title":"Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy","volume":"22","author":"Loo","year":"2002","journal-title":"Retina"},{"key":"R24-3-20240830","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: Towards an evidence-based treatment guideline","volume":"73","author":"van Rijssen","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R25-3-20240830","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"R26-3-20240830","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/IAE.0b013e318175421f","article-title":"Risk factors for posterior cystoid retinal degeneration in central serous chorioretinopathy","volume":"28","author":"Piccolino","year":"2008","journal-title":"Retina"},{"key":"R27-3-20240830","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0161-6420(89)32810-7","article-title":"Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography","volume":"96","author":"Levine","year":"1989","journal-title":"Ophthalmology"},{"key":"R28-3-20240830","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archopht.1984.01040030359038","article-title":"Experimental serous retinal detachment and focal pigment epithelial damage","volume":"102","author":"Negi","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R29-3-20240830","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/00006982-200312000-00002","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy","volume":"23","author":"Cardillo Piccolino","year":"2003","journal-title":"Retina"},{"key":"R30-3-20240830","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ajo.2004.01.043","article-title":"Chronic central serous chorioretinopathy: Photodynamic therapy","volume":"137","author":"Taban","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R31-3-20240830","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000490773","article-title":"Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy","volume":"241","author":"Son","year":"2019","journal-title":"Ophthalmologica"},{"key":"R32-3-20240830","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3341\/kjo.2019.0065","article-title":"Comparison of focal and conventional verteporfin photodynamic therapy for chronic central serous chorioretinopathy","volume":"33","author":"Noh","year":"2019","journal-title":"Korean J Ophthalmol"},{"key":"R33-3-20240830","doi-asserted-by":"crossref","first-page":"e0206646","DOI":"10.1371\/journal.pone.0206646","article-title":"Geographic filling delay of the choriocapillaris in the region of dilated asymmetric vortex veins in central serous chorioretinopathy","volume":"13","author":"Kishi","year":"2018","journal-title":"PLoS One"},{"key":"R34-3-20240830","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.oret.2017.05.013","article-title":"Dilatation of asymmetric vortex vein in central serous chorioretinopathy","volume":"2","author":"Hiroe","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R35-3-20240830","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.oret.2020.07.011","article-title":"Scleral thickness in central serous chorioretinopathy","volume":"5","author":"Imanaga","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R36-3-20240830","doi-asserted-by":"crossref","first-page":"e0227718","DOI":"10.1371\/journal.pone.0227718","article-title":"Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"key":"R37-3-20240830","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4103\/ijo.IJO_1327_19","article-title":"Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy","volume":"68","author":"Sirakaya","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R38-3-20240830","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/TCRM.S138581","article-title":"Neutrophil\/lymphocyte ratio and mean platelet volume in central serous chorioretinopathy","volume":"13","author":"Erol","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R39-3-20240830","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10792-016-0237-0","article-title":"Relationship between mean platelet volume and central serous chorioretinopathy","volume":"37","author":"Dursun","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R40-3-20240830","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2147\/OPTH.S12583","article-title":"Low-dose aspirin as treatment for central serous chorioretinopathy","volume":"4","author":"Caccavale","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R41-3-20240830","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Invest"},{"key":"R42-3-20240830","first-page":"472","article-title":"Electrophysiological effects of corticosteroids on the retinal pigment epithelium","volume":"42","author":"Arndt","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-3-20240830","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/humu.22551","article-title":"Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy","volume":"35","author":"Schubert","year":"2014","journal-title":"Hum Mutat"},{"key":"R44-3-20240830","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"key":"R45-3-20240830","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41433-021-01808-3","article-title":"Pathophysiology of central serous chorioretinopathy: A literature review with quality assessment","volume":"36","author":"Kanda","year":"2022","journal-title":"Eye (Lond"},{"key":"R46-3-20240830","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","article-title":"Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy","volume":"135","author":"van Dijk","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R47-3-20240830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0002-9394(03)00076-X","article-title":"Central serous chorioretinopathy associated with administration of sympathomimetic agents","volume":"136","author":"Michael","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R48-3-20240830","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1167\/iovs.05-1246","article-title":"Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: A case-control study","volume":"47","author":"Tewari","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R49-3-20240830","doi-asserted-by":"crossref","first-page":"100865","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R50-3-20240830","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000441502","article-title":"Central serous chorioretinopathy treatments: A mini review","volume":"55","author":"Iacono","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R51-3-20240830","first-page":"CD011841","article-title":"Interventions for central serous chorioretinopathy: A network meta-analysis","volume":"2015","author":"Salehi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R53-3-20240830","first-page":"291","article-title":"Xenon light-exposure as a treatment of central serous retinopathy (a preliminary report)","volume":"20","author":"Mitsui","year":"1969","journal-title":"Nihon Ganka Kiyo"},{"key":"R54-3-20240830","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/ojo.OJO_29_2018","article-title":"Central serous chorioretinopathy: Current update on management","volume":"11","author":"Manayath","year":"2018","journal-title":"Oman J Ophthalmol"},{"key":"R55-3-20240830","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/bjo.63.10.674","article-title":"Argon laser photocoagulation in the treatment of central serous retinopathy","volume":"63","author":"Leaver","year":"1979","journal-title":"Br J Ophthalmol"},{"key":"R56-3-20240830","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0161-6420(97)30262-0","article-title":"Laser photocoagulation for persistent central serous retinopathy: Results of long-term follow-up","volume":"104","author":"Burumcek","year":"1997","journal-title":"Ophthalmology"},{"key":"R57-3-20240830","first-page":"1504","article-title":"Histopathology of diode and argon laser lesions in rabbit retina. A comparative study","volume":"30","author":"Brancato","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R58-3-20240830","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/112067219200200301","article-title":"Laser treatment of diffuse retinal pigment epitheliopathy","volume":"2","author":"Yannuzzi","year":"1992","journal-title":"Eur J Ophthalmol"},{"key":"R59-3-20240830","first-page":"1567","article-title":"Argon laser treatment of central serous chorioretinopathy","volume":"9","author":"Landers","year":"1977","journal-title":"Ann Ophthalmol"},{"key":"R60-3-20240830","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0161-6420(86)33652-2","article-title":"Argon laser photocoagulation treatment in central serous chorioretinopathy","volume":"93","author":"Robertson","year":"1986","journal-title":"Ophthalmology"},{"key":"R61-3-20240830","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3928\/23258160-20130909-08","article-title":"Micropulse diode laser treatment for chronic central serous chorioretinopathy: A randomized pilot trial","volume":"44","author":"Roisman","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R62-3-20240830","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2415-4-15","article-title":"Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484]","volume":"4","author":"Verma","year":"2004","journal-title":"BMC Ophthalmol"},{"key":"R63-3-20240830","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/112067210401400115","article-title":"Indocyanine green dye-enhanced micropulsed diode laser: A novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy","volume":"14","author":"Ricci","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"R64-3-20240830","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE Trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"R65-3-20240830","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2017-311291","article-title":"Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group","volume":"102","author":"Roca","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R66-3-20240830","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/eye.2011.282","article-title":"Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy","volume":"26","author":"Koss","year":"2012","journal-title":"Eye (Lond"},{"key":"R67-3-20240830","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/eye.2017.293","article-title":"Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: Long-term follow-up","volume":"32","author":"Arsan","year":"2018","journal-title":"Eye"},{"key":"R68-3-20240830","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cxo.12818","article-title":"Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy","volume":"102","author":"Arora","year":"2019","journal-title":"Clin Exp Optom"},{"key":"R69-3-20240830","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000439600","article-title":"Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy","volume":"234","author":"Scholz","year":"2015","journal-title":"Ophthalmologica"},{"key":"R70-3-20240830","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00417-017-3783-x","article-title":"Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser","volume":"255","author":"Gaw\u0119cki","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R71-3-20240830","first-page":"835","article-title":"Histopathological changes following photodynamic therapy in human eyes","volume":"120","author":"Schmidt-Erfurth","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R72-3-20240830","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s00417-002-0517-4","article-title":"Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes","volume":"240","author":"Schl\u00f6tzer-Schrehardt","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R73-3-20240830","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial","volume":"115","author":"Chan","year":"2008","journal-title":"Ophthalmology"},{"key":"R74-3-20240830","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00006982-200304000-00016","article-title":"Photodynamic therapy in chronic central serous chorioretinopathy","volume":"23","author":"Parodi","year":"2003","journal-title":"Retina"},{"key":"R75-3-20240830","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1755-3768.2011.02157.x","article-title":"Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy","volume":"90","author":"Pryds","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R76-3-20240830","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/bjophthalmol-2016-308921","article-title":"Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy","volume":"101","author":"Izumi","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R77-3-20240830","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1755-3768.2008.01408.x","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy","volume":"88","author":"Ruiz-Moreno","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R78-3-20240830","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00417-009-1104-8","article-title":"Prognostic factors related to photodynamic therapy for central serous chorioretinopathy","volume":"247","author":"Moon","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R79-3-20240830","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bjo.2006.090282","article-title":"Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: A short term pilot study","volume":"90","author":"Lai","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R80-3-20240830","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.sjopt.2015.01.007","article-title":"Advances in the treatment of central serous chorioretinopathy","volume":"29","author":"Abouammoh","year":"2015","journal-title":"Saudi J Ophthalmol"},{"key":"R81-3-20240830","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/IAE.0b013e3181a6c028","article-title":"Photodynamic therapy for acute central serous chorioretinopathy: The safe effective lowest dose of verteporfin","volume":"29","author":"Zhao","year":"2009","journal-title":"Retina"},{"key":"R82-3-20240830","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bjo.2010.182121","article-title":"Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy","volume":"95","author":"Lim","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R83-3-20240830","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","article-title":"A 50% vs.30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: One-year results of a randomized clinical trial","volume":"133","author":"Zhao","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R84-3-20240830","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","article-title":"Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: A nonrandomized clinical trial","volume":"149","author":"Reibaldi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R85-3-20240830","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","article-title":"Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy","volume":"37","author":"Cheng","year":"2017","journal-title":"Retina"},{"key":"R86-3-20240830","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/IAE.0000000000000511","article-title":"Choroidal thickness after full-fluence and half-fluence photodynamic therapy in chronic central serous chorioretinopathy","volume":"35","author":"Oh","year":"2015","journal-title":"Retina"},{"key":"R87-3-20240830","first-page":"T8","article-title":"Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (An American Ophthalmological Society Thesis)","volume":"113","author":"Lai","year":"2015","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R88-3-20240830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IAE.0b013e318156777f","article-title":"Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study","volume":"28","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"R89-3-20240830","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/eye.2013.24","article-title":"Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes","volume":"27","author":"Karakus","year":"2013","journal-title":"Eye (Lond"},{"key":"R90-3-20240830","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","article-title":"Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study","volume":"23","author":"Yannuzzi","year":"2003","journal-title":"Retina"},{"key":"R91-3-20240830","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/IAE.0000000000002040","article-title":"Chronic central serous chorioretinopathy: Early and late morphological and functional changes after verteporfin photodynamic therapy","volume":"39","author":"Iacono","year":"2019","journal-title":"Retina"},{"key":"R92-3-20240830","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ophtha.2013.11.040","article-title":"Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy","volume":"121","author":"Lim","year":"2014","journal-title":"Ophthalmology"},{"key":"R93-3-20240830","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ophtha.2014.09.034","article-title":"One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy","volume":"122","author":"Fujita","year":"2015","journal-title":"Ophthalmology"},{"key":"R94-3-20240830","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00417-018-4086-6","article-title":"Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy","volume":"256","author":"Sheptulin","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R95-3-20240830","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/eye.2016.79","article-title":"The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: A case-control study","volume":"30","author":"Ozkaya","year":"2016","journal-title":"Eye (Lond"},{"key":"R96-3-20240830","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/OPTH.S58617","article-title":"Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy","volume":"8","author":"Alkin","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R97-3-20240830","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/IAE.0b013e3181e378f2","article-title":"Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy","volume":"31","author":"Shin","year":"2011","journal-title":"Retina"},{"key":"R98-3-20240830","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajo.2014.01.022","article-title":"Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"157","author":"Nicol\u00f3","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R99-3-20240830","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R100-3-20240830","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2016.04.001","article-title":"Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy","volume":"167","author":"Liu","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R101-3-20240830","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00417-014-2926-6","article-title":"Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy","volume":"253","author":"Kim","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R102-3-20240830","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bjophthalmol-2014-305353","article-title":"Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy","volume":"99","author":"Tseng","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R103-3-20240830","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/IAE.0b013e31820a6a17","article-title":"Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy","volume":"31","author":"Shin","year":"2011","journal-title":"Retina"},{"key":"R104-3-20240830","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3341\/kjo.2010.24.3.155","article-title":"The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy","volume":"24","author":"Lim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R105-3-20240830","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","article-title":"Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells","volume":"91","author":"Peters","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R106-3-20240830","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00417-008-0856-x","article-title":"A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports)","volume":"246","author":"Torres-Soriano","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R107-3-20240830","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/02713680903428306","article-title":"Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: A prospective, controlled clinical study","volume":"35","author":"Artunay","year":"2010","journal-title":"Curr Eye Res"},{"key":"R108-3-20240830","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000345495","article-title":"Intravitreal ranibizumab for acute central serous chorioretinopathy","volume":"229","author":"Kim","year":"2013","journal-title":"Ophthalmologica"},{"key":"R109-3-20240830","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ajo.2009.11.017","article-title":"Central serous chorioretinopathy: A personal perspective","volume":"149","author":"Yannuzzi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R110-3-20240830","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajo.2011.04.008","article-title":"A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy","volume":"152","author":"Bae","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R111-3-20240830","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2013.09.024","article-title":"Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: One-year results of a randomized trial","volume":"121","author":"Bae","year":"2014","journal-title":"Ophthalmology"},{"key":"R112-3-20240830","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","article-title":"A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: The CONTAIN study","volume":"99","author":"Pitcher","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R113-3-20240830","first-page":"265","article-title":"Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy: A single center retrospective study","volume":"33","author":"Tekin","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"R114-3-20240830","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00417-010-1581-9","article-title":"The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy","volume":"249","author":"Lim","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R115-3-20240830","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/eye.2015.58","article-title":"Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients","volume":"29","author":"Kim","year":"2015","journal-title":"Eye (Lond"},{"key":"R116-3-20240830","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/IAE.0000000000001750","article-title":"Anti-vascular endothelial growth factor therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy","volume":"38","author":"Peiretti","year":"2018","journal-title":"Retina"},{"key":"R117-3-20240830","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/08820538.2016.1182556","article-title":"Variation in visual outcome to anti-vascular endothelial growth factors in choroidal neovascular membrane developing in eyes with previously untreated versus focal laser-treated central serous chorioretinopathy","volume":"32","author":"Roy","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"R118-3-20240830","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/2008-322X.180700","article-title":"Intravitreal bevacizumab for treatment of central serous chorioretinopathy","volume":"11","author":"\u00dcnl\u00fc","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"key":"R119-3-20240830","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3341\/kjo.2015.29.3.160","article-title":"The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy","volume":"29","author":"Kim","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"R120-3-20240830","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00417-016-3417-8","article-title":"Central serous chorioretinopathy in primary hyperaldosteronism","volume":"254","author":"van Dijk","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R121-3-20240830","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: Aldosterone up-regulates ion and water channels in M\u00fcller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J"},{"key":"R122-3-20240830","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0161-6420(02)01975-9","article-title":"Endocrine abnormalities in patients with central serous chorioretinopathy","volume":"110","author":"Haimovici","year":"2003","journal-title":"Ophthalmology"},{"key":"R123-3-20240830","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent"},{"key":"R124-3-20240830","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"R125-3-20240830","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00417-016-3373-3","article-title":"Clinical experience with eplerenone to treat chronic central serous chorioretinopathy","volume":"254","author":"Cakir","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R126-3-20240830","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000309115","article-title":"Central serous chorioretinopathy: Some considerations on the pathogenesis","volume":"182","author":"Piccolino","year":"1981","journal-title":"Ophthalmologica"},{"key":"R127-3-20240830","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study","volume":"33","author":"Bousquet","year":"2013","journal-title":"Retina"},{"key":"R128-3-20240830","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy \u2013 A randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"R129-3-20240830","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): A randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R130-3-20240830","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R131-3-20240830","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"R132-3-20240830","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41433-019-0568-y","article-title":"Oral medications for central serous chorioretinopathy: A literature review","volume":"34","author":"Fusi-Rubiano","year":"2020","journal-title":"Eye (Lond"},{"key":"R133-3-20240830","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","article-title":"Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)","volume":"255","author":"Herold","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R134-3-20240830","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","article-title":"Spironolactone versus observation in the treatment of acute central serous chorioretinopathy","volume":"102","author":"Sun","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R135-3-20240830","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ando.2018.03.004","article-title":"Glucocorticoid receptor modulators","volume":"79","author":"Meijer","year":"2018","journal-title":"Ann Endocrinol (Paris"},{"key":"R136-3-20240830","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1097\/IAE.0b013e31821c3ef6","article-title":"Oral mifepristone for chronic central serous chorioretinopathy","volume":"31","author":"Nielsen","year":"2011","journal-title":"Retina"},{"key":"R137-3-20240830","first-page":"782","article-title":"Short-term oral mifepristone for the treatment of central serous chorioretinopathy (STOMP CSC) \u2013 A randomized, placebo-controlled study","volume":"59","author":"Goldberg","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R138-3-20240830","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/IAE.0000000000002507","article-title":"Comparison of visual\/anatomical outcomes and recurrence rate between oral spironolactone and photodynamic therapy for nonresolving central serous chorioretinopathy","volume":"40","author":"Kim","year":"2020","journal-title":"Retina"},{"key":"R139-3-20240830","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2017.295","article-title":"Response of central serous chorioretinopathy evaluated by multimodal retinal imaging","volume":"32","author":"Sacconi","year":"2018","journal-title":"Eye (Lond"},{"key":"R140-3-20240830","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: Real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl Vis Sci Technol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.362040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:34Z","timestamp":1787757394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.362040"}},"subtitle":["Treatment"],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":139,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/2211-5056.362040","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}